Ervaccine Technologies
Lyon
About Ervaccine Technologies
ErVaccine Technologies creates immunotherapies that integrate T-cell treatments with cancer vaccinations to meet a medical need for cold tumors. They are committed to identifying tumor epitopes that are physician. They come from endogenous retroviruses and are novel cancer epitopes. They use a bioinformatics-based strategy to find possible epitopes, which are then verified by proteomics and immunological testing.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $7.8M
- Funding stage: Seed
- Last round: Grant (Oct 2023)
- Website: ervaccinetechnologies.com
Industries & Categories
Biotechnology, Pharmaceutical
Canonical: https://fsome.com/organization/ervaccine-technologies-71373 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.